vs
AVANOS MEDICAL, INC.（AVNS）与CollPlant Biotechnologies Ltd（CLGN）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是CollPlant Biotechnologies Ltd的1010.6倍（$180.9M vs $179.0K）。AVANOS MEDICAL, INC.净利率更高（-0.7% vs -1869.8%，领先1869.1%）。AVANOS MEDICAL, INC.同比增速更快（0.7% vs -28.1%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
CollPlant Biotechnologies是一家再生医疗企业，依托专有的植物源人胶原蛋白技术，开发并商业化伤口护理、软组织修复、医美领域的创新产品，主要面向北美、欧洲及以色列市场，服务皮肤科、骨科和医美领域的医疗从业者。
AVNS vs CLGN — 直观对比
营收规模更大
AVNS
是对方的1010.6倍
$179.0K
营收增速更快
AVNS
高出28.8%
-28.1%
净利率更高
AVNS
高出1869.1%
-1869.8%
损益表 — Q4 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $179.0K |
| 净利润 | $-1.3M | $-3.3M |
| 毛利率 | 47.5% | -3.9% |
| 营业利润率 | 1.4% | -1775.4% |
| 净利率 | -0.7% | -1869.8% |
| 营收同比 | 0.7% | -28.1% |
| 净利润同比 | 99.7% | 20.5% |
| 每股收益（稀释后） | $-0.02 | $0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSCLGN
| Q4 25 | $180.9M | — | ||
| Q3 25 | $177.8M | — | ||
| Q2 25 | $175.0M | $179.0K | ||
| Q1 25 | $167.5M | — | ||
| Q4 24 | $179.6M | — | ||
| Q3 24 | $170.4M | — | ||
| Q2 24 | $171.7M | $249.0K | ||
| Q1 24 | $166.1M | — |
净利润AVNSCLGN
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | — | ||
| Q2 25 | $-76.8M | $-3.3M | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $1.8M | $-4.2M | ||
| Q1 24 | $-900.0K | — |
毛利率AVNSCLGN
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | -3.9% | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | -115.3% | ||
| Q1 24 | 57.1% | — |
营业利润率AVNSCLGN
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -42.6% | -1775.4% | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | -233.0% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 3.7% | -1769.5% | ||
| Q1 24 | 2.4% | — |
净利率AVNSCLGN
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | -43.9% | -1869.8% | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 1.0% | -1690.8% | ||
| Q1 24 | -0.5% | — |
每股收益（稀释后）AVNSCLGN
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-1.66 | $0.28 | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.04 | $0.37 | ||
| Q1 24 | $-0.02 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $11.4M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $12.5M |
| 总资产 | $1.1B | $17.4M |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSCLGN
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | $11.4M | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | $18.9M | ||
| Q1 24 | $75.8M | — |
总债务AVNSCLGN
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSCLGN
| Q4 25 | $778.2M | — | ||
| Q3 25 | $778.0M | — | ||
| Q2 25 | $776.3M | $12.5M | ||
| Q1 25 | $839.4M | — | ||
| Q4 24 | $828.5M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | $20.7M | ||
| Q1 24 | $1.2B | — |
总资产AVNSCLGN
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | $17.4M | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | $26.6M | ||
| Q1 24 | $1.7B | — |
负债/权益比AVNSCLGN
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | — |
| 自由现金流经营现金流 - 资本支出 | $21.3M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 3.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | — |
8季度趋势，按日历期对齐
经营现金流AVNSCLGN
| Q4 25 | $28.2M | — | ||
| Q3 25 | $14.0M | — | ||
| Q2 25 | $6.8M | — | ||
| Q1 25 | $25.7M | — | ||
| Q4 24 | $57.9M | — | ||
| Q3 24 | $23.0M | — | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $-8.0M | — |
自由现金流AVNSCLGN
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
自由现金流率AVNSCLGN
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
资本支出强度AVNSCLGN
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | — |
现金转化率AVNSCLGN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CLGN
暂无分部数据
